In subcutaneous MLS cell line xenograft models, AR30 resulted in partial tumor growth inhibition (TGI) and synergized with cisplatin to significantly reduce tumor growth in part attributable to cisplatin-mediated AREG upregulation [99]. The gene discussed is AREG; the disease is neoplasm.